Amy Gallup Klann is devoted to building and managing patent portfolios for companies in the life sciences industry, with expertise in gene and cell therapy, stem cell-related technologies, immunotherapy, molecular genetics, biologics, and neuroscience. She provides strategic patent counseling and due diligence to clients at all stages of the business cycle, with a particular focus on developing IP strategies and patent portfolios for emerging companies.
Amy’s deep understanding of molecular biology and research and development processes allow her to function closely with her biotech clients, seamlessly melding the role of patent attorney with the research and development team.
Amy managed the lead immuno-oncology portfolio at a major pharmaceutical company, leading both the US and international patent strategies, including numerous European oppositions.
Amy also serves on the Board of the Neural Stem Cell Institute, Rensselaer NY, where she advises on research and development alliances and translational matters in the field of age-related macular degeneration (AMD) as well as neurodegenerative diseases.
Amy is active in the IP community and currently serves on the executive committee of the Hon. William C. Conner Inn of Court, as a member of the Tokyo IP Inn of Court, as a representative on the Linn Inn Alliance Advisory Council, as well as on the steering committee of the international Women in IP Network (WIN). Amy graduated from Va. Wesleyan University in 1989 summa cum laude, from Baylor College of Medicine with her PhD in Microbiology & Immunology in 1993, and from the University of Houston Law Center in 2006 and was admitted to the New York State Bar in 2007. Amy is also registered to practice before the United States Patent & Trademark Office.